AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03500809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aqueous release of the wound
Description: 1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye.
Study NCT01020435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
Study NCT01020435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Spinal Manipulation
Description: The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
Study NCT03132571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)
Study NCT03132571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Study NCT03132571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
Study NCT03467672 — intervention group
Intervention type: OTHER
Intervention: Diagnosis of bacterial infection
Description: use of eosinopenia in the diagnosis of bacterial infection
Study NCT03132571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo taken once daily for the course of the study (16 week)
Study NCT00952640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A
Description: high dose vitamin A, 200.000 IU
Study NCT00952640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A
Description: high dose vitamin A, 200.000 IU
Study NCT03606863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative peripheral parenteral nutrition
Study NCT00458094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with peer support (PA+PS)
Description: Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
Study NCT00458094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity intervention without peer support (PA)
Description: Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
Study NCT03733951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia.
Study NCT01450774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 50/6µg
Description: fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Study NCT04105998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 10 IU
Study NCT04105998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01450774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Description: free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
Study NCT03507699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Liver radiation therapy
Description: 21 Gy in three fractions to one liver metastasis
Study NCT03507699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: administered IV at a dose of 3mg/kg every 2 weeks
Study NCT03507699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: administered IV at a dose of 1mg/kg every 6 weeks
Study NCT03507699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
Study NCT05790759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait
Description: Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
Study NCT04495153 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Aglatimagene besadenovec
Description: Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
Study NCT02643589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
Study NCT02643589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
Study NCT02418286 — intervention group
Intervention type: OTHER
Intervention: expose to any drugs or procedures based on traditional Korean medicine theory
Description: There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
Study NCT03032965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate.
Study NCT03032965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
Study NCT03669224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
Study NCT03669224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
Study NCT03669224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 2 % chlorhexidine gluconate. This group will be compared with no intervention group.
Study NCT04414774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GG-Suicide-Ideation
Description: GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
Study NCT04414774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GG-Suicide-Ideation
Description: GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
Study NCT02765763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Minute Reveal Masque
Study NCT02765763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24/7 Barrier Repair Cream
Study NCT02765763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8-in-1 BioSerum
Study NCT02765763 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Null Formula 2-Minute Reveal Masque
Study NCT02765763 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Null Formula 24/7 Barrier Repair Cream
Study NCT02765763 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Null Formula 8-in-1 BioSerum
Study NCT03101176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: The ultrasound contrast agent used for the CEUS specific ultrasound mode
Study NCT05147012 — intervention group
Intervention type: OTHER
Intervention: Data collected
Description: The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients.
Study NCT01601340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HQK-1001
Description: HQK-1001 tablets, twice daily for 48 weeks
Study NCT01601340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, twice daily for 48 weeks
Study NCT01537939 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASUKI Step Worksite Pedometer Intervention
Description: The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
Study NCT05298826 — intervention group
Intervention type: DRUG
Intervention: recombinant factor VIIa
Description: using recombinant factor VIIa
Study NCT03032965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoproterenol
Description: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
Study NCT04048226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
Study NCT03010683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
Study NCT03010683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
Study NCT01721317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezogabine/Retigabine IR
Description: Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
Study NCT01721317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available
Study NCT02876718 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
Study NCT03980535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03980535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT02216097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: 4mg PF-04457845 tablet taken once daily for 7 days.
Study NCT02216097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet taken once daily for 7 days.
Study NCT01406574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121
Description: Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
Study NCT01406574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121 phase2
Description: Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
Study NCT04214197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Crisaborole 2% Top Oint
Description: Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
Study NCT03672591 — intervention group
Intervention type: OTHER
Intervention: Renal clearance examination
Description: Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
Study NCT02103855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Study NCT02376673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children's Book
Description: A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
Study NCT02376673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Brochures
Description: An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
Study NCT04521738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441255
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT04521738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study NCT04037709 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing (SRP) + PDT placebo
Description: Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
Study NCT04037709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing (SRP) + PDT
Description: patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
Study NCT01810510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAV Ventilation
Description: PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
Study NCT01810510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAVA Ventilation
Description: With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
Study NCT03035578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
Study NCT03035578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population